New study monitors eylea use in preterm infants at risk of blindness
NCT ID NCT06315556
First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 30 times
Summary
This study looks at how often a medicine called Eylea is used in preterm babies with retinopathy of prematurity (ROP), an eye disease that can cause blindness. Researchers will collect data from a UK database on up to 200 babies treated with Eylea using a special pediatric dosing device. The goal is to see if enough babies receive this treatment to later study its long-term safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRETERM INFANTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Many locations
RECRUITINGMultiple Locations, United Kingdom
Conditions
Explore the condition pages connected to this study.